Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Iréne Esposito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0554-2402; OpenAlex author ID A5063785731, A5122242120, A5124163028, A5129370680, A5135314063. Sources: OpenAlex.

Their work

Papers
83 (first author 2, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
254
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 3 papers · 2014: 7 papers · 2015: 9 papers · 2016: 4 papers · 2017: 5 papers · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: 8 papers · 2022: 7 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 16 papers

Papers 50 of 83

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Metamorphoses in pancreatic cancer precursors: the role of simple mucinous cysts†. Co-author DOI 10.1002/path.6493↗
  3. Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. Co-author DOI 10.1007/s00261-026-05486-1↗
  4. Correction: Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. Co-author DOI 10.1007/s00261-026-05656-1↗
  5. The Mesopancreas remains at risk in primary resectable pancreatic cancer patients: time to reappraise resectability criteria? Co-author DOI 10.1016/j.ctarc.2026.101176↗
  6. Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives. Co-author DOI 10.1016/j.dld.2026.03.002↗
  7. Comparative Immune Profiling of Murine and Human Pancreatic Cancer Precursors Reveals Species- and Lesion-Dependent Immune Microenvironments. Last author DOI 10.1016/j.labinv.2026.106143↗
  8. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  9. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  10. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  11. From IPMN to invasive pancreatic cancer: new spatial insights. Co-author DOI 10.1136/gutjnl-2025-337622↗
  12. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  13. Immunological and molecular insights into acinar-ductal metaplasia and atypical flat lesions as precursor lesions of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-026-03643-4↗
  14. The substance P/ Neurokinin-1 receptor signaling drives perineural invasion in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fcell.2026.1876023↗
  15. Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade. Co-author DOI 10.3389/fimmu.2026.1844781↗
  16. GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions Co-author DOI 10.64898/2026.05.22.724502↗
  17. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  18. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  19. Early Detection of Sporadic Pancreatic Cancer Co-author DOI 10.1159/000545424↗
  20. IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sect… Co-author DOI 10.2196/76811↗
  21. Molecular characteristics of early-onset pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13576↗
  22. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  23. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  24. A Single-Molecule Bioelectronic Portable Array for Early Diagnosis of Pancreatic Cancer Precursors. Co-author DOI 10.1002/adma.202304102↗
  25. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Last author DOI 10.1136/gutjnl-2021-326550↗
  26. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Co-author DOI 10.1186/s12943-023-01880-1↗
  27. [Pancreatic cystic space-occupying lesions-Diagnostics, treatment and follow-up care : Current recommendations taking the current German S3 guidelines on pancr… Co-author DOI 10.1007/s00104-022-01616-9↗
  28. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2105691119↗
  29. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  30. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  31. N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pancreatic Cancer? Co-author DOI 10.3390/cancers14071834↗
  32. Communicator-Driven Data Preprocessing Improves Deep Transfer Learning of Histopathological Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14081964↗
  33. Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14143494↗
  34. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. First author DOI 10.1007/s00428-020-02987-2↗
  35. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Co-author DOI 10.1016/j.pan.2021.02.024↗
  36. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  37. Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report. Last author DOI 10.1186/s13256-021-02768-8↗
  38. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00862-y↗
  39. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Last author DOI 10.14670/hh-18-332↗
  40. CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation. Co-author DOI 10.3390/cancers13102462↗
  41. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14010068↗
  42. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. Co-author DOI 10.15252/embj.2019102808↗
  43. Pathology of pancreatic cancer. First author DOI 10.21037/tgh.2019.06.02↗
  44. Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Last author DOI 10.1016/j.pan.2018.04.010↗
  45. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Last author DOI 10.1016/j.pan.2018.05.004↗
  46. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002345↗
  47. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  48. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2017.115↗
  49. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Co-author DOI 10.1038/onc.2016.459↗
  50. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-16826-z↗

Closest collaborators

The 25 strongest of 254 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wolfram Trudo Knoefel · 14 shared papers, 2017–2026 · strength 2.19
  2. Lena Haeberle · 6 shared papers, 2026 · strength 1.99
  3. Lena Häberle · 14 shared papers, 2018–2023 · strength 1.96
  4. Sami Alexander Safi · 9 shared papers, 2018–2026 · strength 1.54
  5. Jens Thomas Siveke · 18 shared papers, 2012–2026 · strength 1.39
  6. Claudio Luchini · 5 shared papers, 2021–2026 · strength 1.17
  7. Jorg H. Kleeff · 18 shared papers, 2011–2026 · strength 1.06
  8. Farid Ziayee · 4 shared papers, 2021–2026 · strength 0.94
  9. Mert Erkan · 14 shared papers, 2011–2026 · strength 0.87
  10. A. Alexander · 3 shared papers, 2026 · strength 0.81
  11. Stephan O. David · 3 shared papers, 2026 · strength 0.81
  12. Anna Melissa Schlitter · 10 shared papers, 2012–2023 · strength 0.80
  13. Roland Michael Schmid · 11 shared papers, 2011–2026 · strength 0.78
  14. Christoph W. Michalski · 12 shared papers, 2011–2026 · strength 0.68
  15. Marija Trajkovic‐Arsic · 8 shared papers, 2012–2026 · strength 0.67
  16. Rickmer Braren · 9 shared papers, 2014–2026 · strength 0.67
  17. Alina Deipenbrock · 2 shared papers, 2026 · strength 0.62
  18. Dirk Weyhe · 2 shared papers, 2026 · strength 0.62
  19. Nicole Elisabeth Teusch · 2 shared papers, 2026 · strength 0.62
  20. Aslihan Yavas · 3 shared papers, 2023–2026 · strength 0.61
  21. Thilo Hackert · 3 shared papers, 2023–2025 · strength 0.59
  22. Tom Luedde · 4 shared papers, 2021–2025 · strength 0.56
  23. Francisco X. Real · 3 shared papers, 2020–2026 · strength 0.56
  24. Bence Sipos · 5 shared papers, 2014–2026 · strength 0.55
  25. İhsan Ekin Demir · 4 shared papers, 2011–2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.